All News


Charity in a cold climate

Can anybody spare a dime for science? With the usual funding avenues blocked development-stage companies are turning to research charities.

Lowering your risk

As life sciences investors shy away from drug development and opt for lower-risk devices and diagnostics, what can Europe learn from Israel’s experience?